During a press conference in Mainz, Germany on Wednesday, BioNTech CEO Ugur Sahin said a third dose of the three-shot course of the Pfizer vaccine neutralized the Omicron COVID-19 variant in a laboratory test.
At the same conference, the company’s chief medical officer said the company was working with Pfizer on an upgraded vaccine that would be effective against the Omicron variant, adding that the vaccine would likely be ready for public use in March 2022.
The comments from BioNTech officials come after study from the Africa Health Research Institute in South Africa (AHRI) found the Omicron variant can partially evade protection from two doses of the Pfizer-BioNTech vaccine.
For more info, please go to
Subscribe to Global News Channel HERE:
Like Global News on Facebook HERE:
Follow Global News on Twitter HERE:
Follow Global News on Instagram HERE:
#Coronavirus #COVID19 #Pfizer #BioNTech #GlobalNews
source